Welcome
About Mucosis
Mucosis B.V. is a Dutch biotechnology company developing innovative mucosal vaccines that can be applied needle-free via the nose or mouth. Mucosis’s lead product candidate is FluGEM™, an intranasal vaccine to prevent influenza. Our vaccines are based on the patented Mimopath™ technology. This technology enables a more natural immune response as well as a broad base of protection.
About Mimopath™ technology
Mimopath™ technology is based on Lactococcus lactis, a safe bacterium commonly used in the food industry. Mucosis has developed an easy technique to formulate the L. lactis bacteria into non-living particles that can be loaded with antigens from viral, bacterial or parasitic origin. The antigen-covered particles form a vaccine that can be delivered into the nose or mouth, without the need for a needle. These vaccines raise protective immunity by activation of both the innate and the adaptive immune system.